Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, discusses UNIVERSAL (NCT04093596): A Phase I, first-in-human study of ALLO-715 and ALLO-647 in relapsed/refractory (R/R) multiple myeloma. These readily available allogeneic CAR T-cell products have the potential to eliminate the need for bridging therapy between autologous stem cell collection and its subsequent infusion. Their use may also reduce the risk of graft-versus-host disease (GvHD) in myeloma patients. This line of treatment was found to have an encouraging safety profile, with no neurotoxicity or cases of GvHD being reported. An overall response rate of 60% was achieved in one of the higher dose levels. Enrollment into the trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.